Clinical Trial Update: PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluates PIN in combination with an anti-PD1 antibody for previously treated hepatocellular carcinoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anti-PD-1 antibody
• PIN (PIN)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hepatocellular Carcinoma, Adult | Phase 1 | Status: RECRUITING